地舒单抗治疗什么病症？

What condition is treated? Desosumab, also known as denosumab and trade name Prolia, is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density. The indications for denosumab are as follows:

On December 17, 2009, the European Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on denosumab (denosumab) for the treatment of postmenopausal osteoporosis in women and hormonal ablation of prostate cancer for the treatment of bone loss in men. Desosumab was approved for marketing by the European Commission on May 28, 2010.

On June 2, 2010, denosumab was approved by the United States (FDA) for use in postmenopausal women with the risk of osteoporosis, under the trade name Prolia.

In November 2010, denosumab (denosumab) was approved for the prevention of bone-related events in patients and the treatment of solid tumors with bone metastases. Desosumab is the first RANKL inhibitor approved by the FDA under the trade name Xgeva.

On June 13, 2013, the U.S. FDA approved denosumab for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or in which resection would result in significant morbidity.

Desosumab can only be given by subcutaneous injection, not by intravenous infusion, intramuscular infusion or intradermal injection. Inject 120 mg subcutaneously into the upper arm, upper thigh, or abdomen every 4 weeks to give calcium and vitamin D when needed to treat or prevent hypocalcemia.

Hypocalcemia must be corrected before denosumab therapy can be initiated. For patients who are prone to hypocalcemia and mineral metabolism imbalance, it is necessary to closely monitor their creatinine and mineral levels in clinical practice, and instruct such patients to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D.

The above is the introduction of the indications of (denosumab). I believe that with the advancement of medical technology, denosumab will bring hope to more and more patients.